vs
Side-by-side financial comparison of ACNB CORP (ACNB) and Vanda Pharmaceuticals Inc. (VNDA). Click either name above to swap in a different company.
Vanda Pharmaceuticals Inc. is the larger business by last-quarter revenue ($57.2M vs $47.2M, roughly 1.2× ACNB CORP). ACNB CORP runs the higher net margin — 22.9% vs -246.8%, a 269.7% gap on every dollar of revenue. On growth, ACNB CORP posted the faster year-over-year revenue change (42.2% vs 7.6%). ACNB CORP produced more free cash flow last quarter ($52.6M vs $-29.5M). Over the past eight quarters, ACNB CORP's revenue compounded faster (22.1% CAGR vs 9.8%).
ACNB Corp is a US-based financial holding company headquartered in Pennsylvania. It provides a full suite of financial solutions including retail and commercial banking, wealth management, trust services, and property & casualty insurance products. Its core market covers local communities, individual consumers, and small-to-medium enterprises across south-central Pennsylvania and northern Maryland.
Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for central nervous system disorders. Its key marketed products cover indications including sleep-wake cycle disturbances and schizophrenia, with core operations and primary sales markets concentrated in North America, catering to patient groups with significant unmet medical needs.
ACNB vs VNDA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $47.2M | $57.2M |
| Net Profit | $10.8M | $-141.2M |
| Gross Margin | — | — |
| Operating Margin | 27.9% | -70.5% |
| Net Margin | 22.9% | -246.8% |
| Revenue YoY | 42.2% | 7.6% |
| Net Profit YoY | 63.8% | -2774.3% |
| EPS (diluted) | $1.10 | $-2.40 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $47.2M | $57.2M | ||
| Q3 25 | $50.9M | $56.3M | ||
| Q2 25 | $50.3M | $52.6M | ||
| Q1 25 | $43.5M | $50.0M | ||
| Q4 24 | $33.2M | $53.2M | ||
| Q3 24 | $34.1M | $47.7M | ||
| Q2 24 | $33.3M | $50.5M | ||
| Q1 24 | $31.6M | $47.5M |
| Q4 25 | $10.8M | $-141.2M | ||
| Q3 25 | $14.9M | $-22.6M | ||
| Q2 25 | $11.6M | $-27.2M | ||
| Q1 25 | $-272.0K | $-29.5M | ||
| Q4 24 | $6.6M | $-4.9M | ||
| Q3 24 | $7.2M | $-5.3M | ||
| Q2 24 | $11.3M | $-4.5M | ||
| Q1 24 | $6.8M | $-4.1M |
| Q4 25 | 27.9% | -70.5% | ||
| Q3 25 | 37.2% | -55.6% | ||
| Q2 25 | 29.7% | -73.2% | ||
| Q1 25 | -1.3% | -82.0% | ||
| Q4 24 | 24.8% | -19.3% | ||
| Q3 24 | 27.6% | -23.1% | ||
| Q2 24 | 42.8% | -20.1% | ||
| Q1 24 | 26.9% | -19.5% |
| Q4 25 | 22.9% | -246.8% | ||
| Q3 25 | 29.2% | -40.1% | ||
| Q2 25 | 23.2% | -51.7% | ||
| Q1 25 | -0.6% | -58.9% | ||
| Q4 24 | 19.9% | -9.2% | ||
| Q3 24 | 21.1% | -11.2% | ||
| Q2 24 | 33.9% | -9.0% | ||
| Q1 24 | 21.4% | -8.7% |
| Q4 25 | $1.10 | $-2.40 | ||
| Q3 25 | $1.42 | $-0.38 | ||
| Q2 25 | $1.11 | $-0.46 | ||
| Q1 25 | $-0.03 | $-0.50 | ||
| Q4 24 | $0.77 | $-0.09 | ||
| Q3 24 | $0.84 | $-0.09 | ||
| Q2 24 | $1.32 | $-0.08 | ||
| Q1 24 | $0.80 | $-0.07 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $65.6M | $84.9M |
| Total DebtLower is stronger | $255.4M | — |
| Stockholders' EquityBook value | $420.0M | $327.2M |
| Total Assets | $3.2B | $488.9M |
| Debt / EquityLower = less leverage | 0.61× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $65.6M | $84.9M | ||
| Q3 25 | $102.1M | $70.0M | ||
| Q2 25 | $103.1M | $81.0M | ||
| Q1 25 | $123.6M | $111.8M | ||
| Q4 24 | $47.3M | $102.3M | ||
| Q3 24 | $58.1M | $100.5M | ||
| Q2 24 | $86.3M | $103.0M | ||
| Q1 24 | $53.1M | $125.2M |
| Q4 25 | $255.4M | — | ||
| Q3 25 | $255.4M | — | ||
| Q2 25 | $255.4M | — | ||
| Q1 25 | $255.3M | — | ||
| Q4 24 | $255.3M | — | ||
| Q3 24 | $255.3M | — | ||
| Q2 24 | $255.3M | — | ||
| Q1 24 | $255.3M | — |
| Q4 25 | $420.0M | $327.2M | ||
| Q3 25 | $408.6M | $466.0M | ||
| Q2 25 | $395.2M | $486.3M | ||
| Q1 25 | $386.9M | $511.4M | ||
| Q4 24 | $303.3M | $538.5M | ||
| Q3 24 | $306.8M | $541.2M | ||
| Q2 24 | $289.3M | $542.5M | ||
| Q1 24 | $279.9M | $544.0M |
| Q4 25 | $3.2B | $488.9M | ||
| Q3 25 | $3.3B | $601.1M | ||
| Q2 25 | $3.3B | $624.7M | ||
| Q1 25 | $3.3B | $631.9M | ||
| Q4 24 | $2.4B | $656.2M | ||
| Q3 24 | $2.4B | $645.1M | ||
| Q2 24 | $2.5B | $651.4M | ||
| Q1 24 | $2.4B | $652.7M |
| Q4 25 | 0.61× | — | ||
| Q3 25 | 0.62× | — | ||
| Q2 25 | 0.65× | — | ||
| Q1 25 | 0.66× | — | ||
| Q4 24 | 0.84× | — | ||
| Q3 24 | 0.83× | — | ||
| Q2 24 | 0.88× | — | ||
| Q1 24 | 0.91× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $53.6M | $-29.4M |
| Free Cash FlowOCF − Capex | $52.6M | $-29.5M |
| FCF MarginFCF / Revenue | 111.4% | -51.6% |
| Capex IntensityCapex / Revenue | 2.3% | 0.2% |
| Cash ConversionOCF / Net Profit | 4.96× | — |
| TTM Free Cash FlowTrailing 4 quarters | $92.2M | $-110.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $53.6M | $-29.4M | ||
| Q3 25 | $23.2M | $-31.6M | ||
| Q2 25 | $17.8M | $-15.3M | ||
| Q1 25 | $-71.0K | $-33.1M | ||
| Q4 24 | $39.8M | $-1.8M | ||
| Q3 24 | $13.6M | $-14.6M | ||
| Q2 24 | $9.7M | $-6.9M | ||
| Q1 24 | $10.8M | $7.6M |
| Q4 25 | $52.6M | $-29.5M | ||
| Q3 25 | $22.8M | $-31.8M | ||
| Q2 25 | $17.6M | $-15.6M | ||
| Q1 25 | $-730.0K | $-33.6M | ||
| Q4 24 | $38.8M | $-2.0M | ||
| Q3 24 | $13.3M | $-14.7M | ||
| Q2 24 | $9.4M | $-7.0M | ||
| Q1 24 | $10.7M | $7.6M |
| Q4 25 | 111.4% | -51.6% | ||
| Q3 25 | 44.7% | -56.5% | ||
| Q2 25 | 35.0% | -29.6% | ||
| Q1 25 | -1.7% | -67.1% | ||
| Q4 24 | 117.0% | -3.8% | ||
| Q3 24 | 39.1% | -30.9% | ||
| Q2 24 | 28.3% | -13.9% | ||
| Q1 24 | 33.9% | 15.9% |
| Q4 25 | 2.3% | 0.2% | ||
| Q3 25 | 0.8% | 0.3% | ||
| Q2 25 | 0.4% | 0.6% | ||
| Q1 25 | 1.5% | 0.9% | ||
| Q4 24 | 2.9% | 0.4% | ||
| Q3 24 | 0.7% | 0.3% | ||
| Q2 24 | 0.9% | 0.2% | ||
| Q1 24 | 0.2% | 0.0% |
| Q4 25 | 4.96× | — | ||
| Q3 25 | 1.56× | — | ||
| Q2 25 | 1.52× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 6.03× | — | ||
| Q3 24 | 1.88× | — | ||
| Q2 24 | 0.86× | — | ||
| Q1 24 | 1.60× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACNB
Segment breakdown not available.
VNDA
| Fanapt | $33.2M | 58% |
| Hetlioz | $16.4M | 29% |
| PONVORY | $7.6M | 13% |
